Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 11, 2026

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies.

View Full Paper
Ask AI
Bookmark
Share

Authors

LCLucia ChenAAAdolfo AlemanMLMarta Larráyoz

Discussion

Loading...

Member takes

Overview

Randomized trial shows Mezigdomide reduces T cell dysfunction in multiple myeloma, improving anti-myeloma therapies.

Key Points

  • The study aims to investigate how Ikaros degradation by Mezigdomide affects T cell dysfunction and improves efficacy of anti-myeloma therapies.
  • Utilized bone marrow samples from multiple myeloma patients to evaluate T cell populations.
  • Conducted in vitro experiments to assess the effects of Mezigdomide on T cell function and cytotoxicity.
  • Employed ATAC-seq, ChIP-seq, HiC, and RNA-seq to explore the regulatory roles of Ikaros.
  • Mezigdomide treatment reduced dysfunctional T cell populations expressing exhaustion markers like TIGIT.
  • Enhanced cytotoxicity and function of T cells were observed with Mezigdomide in vitro.
  • Improved survival outcomes were demonstrated in vivo following anti-BCMA CAR-T therapy with Mezigdomide.

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/6a01723a3a9f334c28272616https://doi.org/10.1182/blood.2025030891
View Full Paper
Ask AI
Bookmark
Share